Palopegteriparatide
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
THE KEY DATA FROM THE 2025 ESE/ESPE CONGRESS: Chronic hypoparathyroidism in adults.
Journal: Annales d'endocrinologie
Published: January 28, 2026
Treatment of hypoparathyroidism (HypoPT): Position Statement of the Expert Group for Polish Society of Endocrinology - update 2026.
Journal: Endokrynologia Polska
Published: January 07, 2026
Reflections on prevention and treatment of post-thyroidectomy hypoparathyroidism: current management approaches and future prospects.
Journal: Frontiers in endocrinology
Published: December 15, 2025
Management of patients with hypoparathyroidism: a Delphi consensus analysis.
Journal: Journal of endocrinological investigation
Published: December 11, 2025
Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism.
Journal: JCEM case reports
Published: December 10, 2025
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: August 26, 2025
Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug.
Journal: Annals of medicine and surgery (2012)
Published: August 11, 2025
The Drug Update: Recent drug approvals, summer 2025 edition.
Journal: The Nurse practitioner
Published: July 29, 2025
Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA).
Journal: Advances in therapy
Published: July 08, 2025
Unveiling the complexities of hypoparathyroidism: a comprehensive review of clinical manifestations, diagnosis, and novel therapies.
Journal: Journal of endocrinological investigation
Published: July 05, 2025
Last Updated: 04/28/2026